Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors

Oncogene

Volumn 35, Issue 1, 2016, Pages 125-134

  Rodriguez Perales, S ^a   Torres Ruiz, R ^b   Suela, J ^a   Acquadro, F ^a   Martin, M C ^a   Yebra, E ^c   Ramirez, J C ^b   Alvarez, S ^a   Cigudosa, J C ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTARABINE; HYBRID PROTEIN; RUNX1 ETO FUSION PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; RUNX1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME 1; CHROMOSOME 21; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FUSION GENE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KARYOTYPE; LEUKEMOGENESIS; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; POLYADENYLATION; PRIORITY JOURNAL; STOP CODON; GENE TRANSLOCATION; GENETICS; METABOLISM; PATHOLOGY;

AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; TRANSLOCATION, GENETIC;

EID: 84954392687     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.70     Document Type: Article

References (63)

1. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004: 80-97.
2. Friedman AD. Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol 2009; 219: 520-524.
3. Niebuhr BB, Fischer MM, Täger MM, Cammenga JJ, Stocking CC. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis 2008; 40: 8-8.
4. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991; 88: 10431-10434.
5. Hayashi KK, Natsume WW, Watanabe TT, Abe NN, Iwai NN, Okada HH et al. Diminution of the AML1 transcription factor function causes differential effects on the fates of CD4 and CD8 single-positive T cells. J Immunol 2000; 165: 6816-6824.
6. Kurokawa MM, Hirai HH. Role of AML1/Runx1 in the pathogenesis of hematological malignancies. Cancer Sci 2003; 94: 841-846.
7. Miyoshi OSMHIYSO, Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acid Res 1995; 23: 1-8.
8. Liu X, Zhang Q, Zhang DE, Zhou C, Xing H, Tian Z et al. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia 2009; 23: 739-745.
9. Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995; 14: 341-350.
10. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, Enver T. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med 2007; 4: e172.
11. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004; 23: 4284-4296.
12. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348-2357.
13. Osato M, Yanagida M, Shigesada K, Ito Y. Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 2001; 74: 245-251.
14. Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T et al. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosomes Cancer 2003; 38: 1-7.
15. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316-2324.
16. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308-1316.
17. Silva FPG, Lind A, Brouwer-Mandema G, Valk PJM, Giphart-Gassler M. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 2007; 92: 1123-1126.
18. Roumier C, Eclache V, Imbert M, Davi F, MacIntyre E, Garand R et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francąis d'Hématologie Cellulaire (GFHC) and the Groupe Francąis de Cytogénétique Hématologique (GFCH). Blood 2003; 101: 1277-1283.
19. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000; 96: 2862-2869.
20. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999. 93: 1817-1824.
21. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
22. Yamagata T, Maki K, Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 2005; 82: 1-8.
23. Tang J-L, Hou H-A, Chen C-Y, Liu C-Y, Chou W-C, Tseng M-H et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114: 5352-5361.
24. Chen C-Y, Lin L-I, Tang J-L, Ko B-S, Tsay W, Chou W-C et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405-414.
25. Hagemeijer A, Garson OM, Kondo K. Fourth International Workshop on Chromosomes in Leukemia 1982: Translocation (8;21)(q22;q22) in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1984; 11: 284-287.
26. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
27. Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 2010; 5: e12197.
28. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris M-J, Férec C, De Braekeleer M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol 2011; 7: 77-91.
29. Chinen Y, Taki T, Nishida K, Shimizu D, Okuda T, Yoshida N et al. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene 2008; 27: 2249-2256.
30. Agerstam H, Lilljebjörn H, Lassen C, Swedin A, Richter J, Vandenberghe P et al. Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2007; 46: 635-643.
31. Nguyen TT, Ma LN, Slovak ML, Bangs CD, Cherry AM, Arber DA. Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia. Genes Chromosomes Cancer 2006; 45: 918-932.
32. Stevens-Kroef M-JPL, Schoenmakers EFPM, van Kraaij M, Huys E, Vermeulen S, van der Reijden B et al. Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML. Leukemia 2006; 20: 1187-1189.
33. Mikhail FM, Coignet L, Hatem N, Mourad ZI, Farawela HM, Kaffash El DM et al. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004; 39: 110-118.
34. Ramsey H, Zhang D-E, Richkind K, Burcoglu-O'Ral A, Hromas R. Fusion of AML1/Runx1 to copine VIII, a novel member of the copine family, in an aggressive acute myelogenous leukemia with t(12;21) translocation. Leukemia 2003; 17: 1665-1666.
35. Hromas R, Busse T, Carroll A, Mack D, Shopnick R, Zhang DE et al. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood 2001; 97: 2168-2170.
36. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci USA 1993; 90: 7784-7788.
37. Maki K, Sasaki K, Sugita F, Nakamura Y, Mitani K. Acute myeloid leukemia with t(7;21)(q11.2;q22) expresses a novel, reversed-sequence RUNX1-DTX2 chimera. Int J Hematol 2012; 96: 268-273.
38. Proudfoot NJ. Ending the message: poly(A) signals then and now. Genes Dev 2011; 25: 1770-1782.
39. Cherry AM, Bangs CD, Jones P, Hall S, Natkunam Y. A unique AML1 (CBF2 A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia. Cancer Genet Cytogenet 2001; 129: 155-160.
40. Aoki T, Miyamoto T, Yoshida S, Yamamoto A, Yamauchi T, Yoshimoto G et al. Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9. Int J Hematol 2008; 88: 571-574.
41. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
42. Zhang DE, Hetherington CJ, Chen HM, Tenen DG. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colonystimulating factor receptor. Mol Cell Biol 1994; 14: 373-381.
43. Wei H, Liu X, Xiong X, Wang Y, Rao Q, Wang M et al. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain. FEBS Lett 2008; 582: 2167-2172.
44. Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S et al. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 2012; 26: 1329-1337.
45. Matsuura S, Komeno Y, Stevenson KE, Biggs JR, Lam K, Tang T et al. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. Blood 2012; 120: 4028-4037.
46. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104: 1474-1481.
47. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003; 102: 4369-4376.
48. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1Bdependent transcriptional activation. Mol. Cell. Biol. 1995; 15: 1974-1982.
49. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997; 158: 2251-2258.
50. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995; 11: 2667-2674.
51. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000; 96: 2108-2115.
52. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98: 10398-10403.
53. Lawrence HJ, Christensen J, Fong S, Hu Y-L, Weissman I, Sauvageau G et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 2005; 106: 3988-3994.
54. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 1999; 13: 687-698.
55. Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Kömüves L et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999; 13: 1993-1999.
56. Afonja O, Smith JE, Cheng DM, Goldenberg AS, Amorosi E, Shimamoto T et al. MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 2000; 24: 849-855.
57. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 2002; 16: 186-195.
58. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Eng J Med 2004; 350: 1605-1616.
59. Yeh J-RJ, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 2008; 135: 401-410.
60. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 1991; 3: 189-201.
61. Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez-Perales S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat Commun 2014; 5: 3964.
62. Torres R, Garcia A, Jimenez M, Rodriguez S, Ramirez JC. An integration-defective lentivirus-based resource for site-specific targeting of an edited safe-harbour locus in the human genome. Gene Ther 2014; 21: 343-352.
63. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2006; 282: 3428-3432.